298 related articles for article (PubMed ID: 15871555)
1. Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.
Chapman TM; Noble S; Goa KL
Treat Endocrinol; 2003; 2(1):71-6. PubMed ID: 15871555
[TBL] [Abstract][Full Text] [Related]
2. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
Chapman TM; Noble S; Goa KL
Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
4. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
5. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
Reynolds NA; Wagstaff AJ
Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
[TBL] [Abstract][Full Text] [Related]
6. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
7. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes.
Velojic-Golubovic M; Mikic D; Pesic M; Dimic D; Radenkovic S; Antic S
J Endocrinol Invest; 2009 Jan; 32(1):23-7. PubMed ID: 19337010
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
9. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
10. Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus.
Velásquez-Mieyer PA; Neira CP
Expert Opin Pharmacother; 2008 Sep; 9(13):2377-82. PubMed ID: 18710361
[TBL] [Abstract][Full Text] [Related]
11. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
12. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes.
Chen JW; Lauritzen T; Bojesen A; Christiansen JS
Diabetes Obes Metab; 2006 Nov; 8(6):682-9. PubMed ID: 17026493
[TBL] [Abstract][Full Text] [Related]
13. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
14. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
15. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
Wilde MI; McTavish D
Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.
Bode BW; Strange P
Diabetes Care; 2001 Jan; 24(1):69-72. PubMed ID: 11194244
[TBL] [Abstract][Full Text] [Related]
17. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
[TBL] [Abstract][Full Text] [Related]
18. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
[TBL] [Abstract][Full Text] [Related]
19. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
Davidson JA; Liebl A; Christiansen JS; Fulcher G; Ligthelm RJ; Brown P; Gylvin T; Kawamori R
Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
[TBL] [Abstract][Full Text] [Related]
20. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70.
Ohira M; Endo K; Oyama T; Yamaguchi T; Ban N; Kawana H; Nagayama D; Nagumo A; Saiki A; Murano T; Watanabe H; Miyashita Y; Shirai K
Metabolism; 2011 Jan; 60(1):78-85. PubMed ID: 20667560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]